CFDE Data Portal | Search MTND4P24

	Label	Description
	MTND4P24 Gene (Entity type)	ENSG00000232177 - MT-ND4 pseudogene 24
	GSE77108 saha 4 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 11 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE85880 GSE85881 tretinoin cardiac muscle cell 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE223313 naringenin 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE139540 menadione 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE134029 cisplatin 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE218060 decitabine T cell 7 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE204969 GSE204970 tryptophan 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE178975 GSE178978 EGFR inhibition 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS

MTND4P24

ENSG00000232177 - MT-ND4 pseudogene 24

GSE77108 saha 4 v 7 human up

A Gene Set from LINCS

GSE252944 AKT inhibition 11 v 0 human up

A Gene Set from LINCS

GSE85880 GSE85881 tretinoin cardiac muscle cell 0 v 1 human up

A Gene Set from LINCS

GSE223313 naringenin 1 v 2 human up

A Gene Set from LINCS

GSE139540 menadione 4 v 1 human dn

A Gene Set from LINCS

GSE134029 cisplatin 3 v 1 human up

A Gene Set from LINCS

GSE218060 decitabine T cell 7 v 3 human dn

A Gene Set from LINCS

GSE204969 GSE204970 tryptophan 2 v 4 human up

A Gene Set from LINCS

GSE178975 GSE178978 EGFR inhibition 1 v 2 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.